|
1) Taylor OD, Edward LB, Aurora P, et al. Registry of the International Heart and Lung Transplantation: Twenty-fifth Official Adult Heart Transplant Report-2008. J Heart Lung Transplant. 2008; 28: 943-56
|
|
|
|
|
2) Uriel N, Jorde UP, Cotarlan V, et al. Heart transplantation in human immunodeficiency virus-positive patients. J Heart Lung Transplant. 2009; 28: 667-9
|
|
|
|
|
3) Eisen HJ, Hobbs RE, Davis SF, et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine–results at 24 months after transplantation. Transplantation. 2001; 71: 70-8
|
|
|
|
|
|
4) Ekberg H, Tedesco-Silva H, Demirbas A, et al; for the ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357: 2562-75
|
|
|
|
|
|
5) Meiser BM, Groetzner J, Kaczmarek I, et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients？ Transplantation. 2004; 78: 591-8
|
|
|
|
|
|
6) Kobashigawa JA, Miller LW, Russell SD, et al. Study Investigators. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006; 6: 1377-86
|
|
|
|
|
|
7) Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant. 2006; 6: 1377-86
|
|
|
|
|
|
8) Lubitz SA, Baran DA, Alwarshetty MM, et al. Long-term results of tacrolimus monotherapy in cardiac transplant recipients. J Heart Lung Transplant. 2006; 25: 699-706
|
|
|
|
|
|
9) Delgado DH, Rao V, Hamel J, et al. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes. J Heart Lung Transplant. 2005; 24: 1343-6
|
|
|
|
|
|
10) Morris RE, Hoyt EG, Murphy MP, et al. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc. 1990; 22: 1659-62
|
|
|
|
|
|
11) Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998; 66: 507-15
|
|
|
|
|
|
12) Eisen HJ, Kobashigawa J, Keogh A, et al. Mycophenolate Mofetil Cardiac Study Investigators. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005; 24: 517-25
|
|
|
|
|
|
13) Kobashigawa JA, Tobis JM, Mentzer RM, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant. 2006; 6(5 Pt 1): 993-7
|
|
|
|
|
|
14) van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008; 86: 1043-51
|
|
|
|
|
|
15) Wada K, Takada M, Ueda T, et al. Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. Circ J. 2007; 71: 289-93
|
|
|
|
|
16) Wada K, Takada M, Kotake T, et al. Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients: comparison of cyclosporin and tacrolimus treatment. Circ J. 2007; 71: 1022-8
|
|
|
|
|
|
17) Opelz G, Döhler B, Laux G. Collaborative Transplant Study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant. 2005; 5(4 Pt 1): 720-8
|
|
|
|
|
|
18) Teuteberg JJ, Shullo M, Zomak R, et al. Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection. Clin Transplant. 2008; 22: 730-7
|
|
|
|
|
|
19) Eisen HJ, Tuzcu EM, Dorent R, et al; RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003; 349: 847-58
|
|
|
|
|
|
20) Zuckermann AO, Aliabadi AZ. Calcineurin-inhibitor minimization protocols in heart transplantation. Transpl Int. 2009; 22: 78-89
|
|
|
|
|
|
21) Groetzner J, Kaczmarek I, Schulz U, et al. VENINAHTx-Investigators. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation. 2009; 87: 726-33
|
|
|
|
|
|
22) Deng MC, Eisen HJ, Mehra MR, et al. CARGO Investigators. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006; 6: 150-60
|
|
|
|
|
|
23) Mehra MR, Kobashigawa JA, Deng MC, et al. CARGO Investigators. Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection. J Heart Lung Transplant. 2008; 27: 297-301
|
|
|
|
|
|
24) Yamani MH, Taylor DO, Rodriguez ER, et al. Transplant vasculopathy is associated with increased AlloMap gene expression score. J Heart Lung Transplant. 2007; 26: 403-6
|
|
|
|
|
|
25) Billingham ME. Diagnosis of cardiac rejection by endomyocardial biopsy. Heart Transplant. 1992; 1: 25-30
|
|
|
|
|
|
26) Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. Heart Lung Transplant. 2005; 24: 1710-20
|
|
|
|
|
|
27) Reed EF, Demetris AJ, Hammond E, et al. International Society for Heart and Lung Transplantation. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006; 25: 153-9
|
|
|
|
|
|
28) Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 1990; 323: 1723-8
|
|
|
|
|
|
29) Kaufman DB, Shapiro R, Lucey MR, et al. Immunosuppression: practice and trends. Am J Transplant. 2004; 4 Suppl 9: 38-53
|
|
|
|
|
|
30) Kaczmarek I, Deutsch MA, Sadoni S, et al. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. J Heart Lung Transplant. 2007; 26: 511-5
|
|
|
|
|
|
31) Bierl C, Miller B, Prak EL, et al. Antibody-mediated rejection in heart transplant recipients: potential efficacy of B-cell depletion and antibody removal. Clin Transpl. 2006: 489-96
|
|
|
|
|
|
32) Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998; 66: 800-5
|
|
|
|
|